Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies

Clinical and Experimental Immunology

Volumn 183, Issue 3, 2016, Pages 326-340

  Jucaud, V ^a   Ravindranath, M H ^a   Terasaki, P I ^a   Morales Buenrostro, L E ^b   Hiepe, F ^c,d   Rose, T ^c,d   Biesen, R ^c,d  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Autoantibodies; Disease activity; HLA F; HLA Ib; Systemic lupus erythematosus

Indexed keywords

BETA 2 MICROGLOBULIN; CARDIOLIPIN; CELL NUCLEUS DNA; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID; ANTI-IGG; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; HLA-F ANTIGENS; IMMUNOGLOBULIN G;

ADULT; AGED; ALLELE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENETIC ASSOCIATION; GROUPS BY AGE; HUMAN; IMMUNOGENICITY; LYMPHOCYTE; PREVALENCE; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RECURRENT DISEASE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; BIOMARKERS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SYMPTOM FLARE UP; YOUNG ADULT;

EID: 84958926700     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12724     Document Type: Article

References (63)

1. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119-29.
2. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33:167-240.
3. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of anti-nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55:900-4.
4. Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1495-504.
5. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: Lahita RG, ed. Systemic lupus erythematosus, 3rd edn. San Diego, CA: Academic Press, 1999: 1-16.
6. Terasaki PI, Mottironi VD, Barnett EV. Cytotoxins in disease autocytotoxins in lupus. N Engl J Med 1970; 283:724-8.
7. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481-90.
8. Müller-Suur C, Larsson PH, Larsson K. T cell activation by organic dust in vitro. Respir Med 2000; 94:821-7.]
9. Zhou B, Saito S, Nakazawa N et al. Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self-antigens in human serum. Tissue Antigens 2008; 72:98-104.
10. De Azevedo Silva J, Addobbati C, Sandrin-Garcia P, Crovella S. Systemic lupus erythematosus: old and new susceptibility genes versus clinical manifestations. Curr Genomics 2014; 15:52-65.
11. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-39.
12. European Bioinformatics Institute. HLA-I Alleles. Available at: http://www.ebi.ac.uk/ipd/imgt/hla (accessed 2013).
13. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007; 109:2806-14.
14. Allard M, Oger R, Vignard V et al. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLOS ONE 2011; 6:e21118.
15. Wei XH, Orr HT. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990; 29:131-42.
16. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248:220-3.
17. Kovats S, Librach C, Fisch P et al. Expression and possible function of HLA-G chain in human cytotrophoblasts. In: Chaouat G, Mowbray J, eds. Cellular and molecular biology of the materno-fetal relationship. London: INSERM/John Libbey Eurotxt Ltd, 1991:21-9.
18. Rosado S, Perez-Chacon G, Mellor-Pita S et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol 2008; 69:9-15.
19. Park GM, Lee S, Park B et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004; 313:606-11.
20. Bahri R, Hirsch F, Josse A et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 2006; 176:1331-9.
21. Ishitani A, Sageshima N, Lee N et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003; 171:1376-84.
22. Lee N, Geraghty DE. HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003; 171:5264-71.
23. Lepin EJ, Bastin JM, Allan DS et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30:3552-61.
24. Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010; 40:2308-18.
25. Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010; 184:6199-208.
26. Morandi F, Cangemi G, Barco S et al. Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int 2013; 2013:956878.
27. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
29. Isenberg DA, Rahman A, Allen E et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxf) 2005; 44:902-6.
30. Yee CS, Farewell V, Isenberg DA et al. Revised British Isles Lupus Assessment Group 2004 Index. Arthritis Rheum 2006; 54:3300-5.
31. Yee CS, Cresswell L, Farewell V et al. Numerical scoring for the BILAG-2004 index. Rheumatology 2010; 49:1665-9.
32. Gladmann DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288-91.
33. Romero-Diaz J, Isenberg DA, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus. Arthritis Care Res 2011; 63:S37-46.
34. Ravindranath MH, Selvan SR, Terasaki PI. Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients. J Immunotoxicol 2012; 9:282-91.
35. Ravindranath MH, Pham T, Ozawa M, Terasaki PI. Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients. Int Immunol 2012; 24:43-57.
36. Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Therapeutic preparations of IVIg contains naturally occurring anti-HLA-E Abs that react with HLA-Ia (HLA-A/-B/-Cw) alleles. Blood 2013; 121:2013-28.
37. Ravindranath MH, Pham T, El-Awar N, Kaneku H, Terasaki PI. Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies. Mol Immunol 2011; 48:423-30.
38. Ravindranath MH, Taniguchi M, Chen CW et al. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol 2010; 47:1121-31.
39. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol 2010; 185:1935-48.
40. Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxf) 2011; 50:982-8.
41. Ravindranath MH, Terasaki PI, Kawakita S. Naturally occurring anti-HLA-E autoantibodies: evidences of HLA-Ia reactivity of anti-HLA-E antibodies, Chapter 35. In: Shoenfeld Y, Gershwin ME, Meroni PI, eds. Autoantibodies. Amsterdam, Netherlands: Elsevier, 2014:1-9.
42. Wainwright SD, Biro PA, Holmes CH. HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000; 164:319-28.
43. Bresciani A, Pirozzi G, Spera M et al. Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens 1998; 52:44-50.
44. Adamashvili I, Wolf R, Aultman D et al. Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus. Rheumatol Int 2003; 23:294-300.
45. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: marker and modulators of an immune response? Immunol Today 1995; 16: 124-7.
46. Tabayoyong WB, Zavazava N. Soluble HLA revisited. Leuk Res 2007; 31: 121-5.
47. Fainardi E, Rizzo R, Melchiorri L et al. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis. Mult Scler 2008; 14: 446-54.
48. Campoli M, Ferrone S. Tumour escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008; 72: 321-34.
49. Migliaresi S, Bresciani A, Ambrosone L et al. Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia. Ann Rheum Dis 2000; 59:20-5.
50. Murdaca G, Contini P, Setti M et al. Soluble human leukocyte antigen-G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment. Hum Immunol 2011; 72:712-6.
51. Murdaca G, Contini P, Setti M et al. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. Clin Immunol 2009; 133:238-44.
52. Murdaca G, Contini P, Setti M et al. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome. Hum Immunol 2007; 68:894-900.
53. Puppo F, Brenci S, Lanza L et al. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum Immunol 1994; 40: 259-66.
54. Gros F, Cabillic F, Toutirais O, Maux AL, Sebti Y, Amiot L. Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol 2008; 38:742-9.]
55. Zavazava N, Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2:1005-10.
56. Lindaman A, Dowden A, Zavazava N. Soluble HLA-G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol 2006; 56:68-76.
57. Spaggiari GM, Contini P, Dondero A et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002; 100:4098-107.
58. Spaggiari GM, Contini P, Carosio R et al. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 2002; 99:1706-14.
59. Fournel S, Aguerre-Girr M, Huc X et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164:6100-4.
60. Puppo F, Contini P, Ghio M et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000; 12:195-203.
61. Hagihara M, Shimura T, Yamamoto K et al. Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus. Tokai J Exp Clin Med 1993; 18:61-4.
62. Tsuchiya N, Shiota M, Yamaguchi A, Ito K. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:792-6.
63. Kippner L, Klint C, Sturfelt G, Bengtsson AA, Eriksson H, Truedsson L. Increased level of soluble HLA class I antigens in systemic lupus erythematosus: correlation with anti-DNA antibodies and leukopenia. J Autoimmun 2001; 16:471-8.